Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability
https://doi.org/10.15690/vsp.v17i6.1975
Abstract
Due to the recent introduction of golimumab into paediatric rheumatology practice, an overview of the clinical studies of this tumour necrosis factor alpha inhibitor, most of which were conducted with adult patients with rheumatic diseases, has been presented. Clinical laboratory effects and tolerability of golimumab in the form of subcutaneous injections have been analysed for rheumatoid arthritis, psoriatic arthritis, and spondylitis. Evaluation of the efficacy and tolerability of golimumab in long-term observational studies (up to 5 years) has been discussed.
Keywords
rheumatoid arthritis,
psoriatic arthritis,
ankylosing spondylitis,
non-radiographic spondylitis,
golimumab,
efficacy,
tolerability,
pediatric rheumatology practice
Supporting agencies: The article has been published with the support of MSD Pharmaceuticals Ltd
About the Author
Natal’ya N. Chichasova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Disclosure of interest:
Russian Federation
Disclosure of interest:
N.V. Chichasova received fees for consulting services in the field of scientific and educational activities (educational services, scientific articles, participation in expert councils, participation in research, etc.) from MSD Pharmaceuticals Ltd.
References
1. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi: 10.1136/annrheumdis-2016-210715.
2. Revmatologiya. Rossiiskie klinicheskie rekomendatsii. Ed by Nasonov EL. Moscow: GEOTAR-Media; 2017. 456 p. (In Russ).
3. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD trial. Ann Rheum Dis. 2009;68(6):789–796. doi: 10.1136/ard.2008.099010.
4. Keystone EC, Genovese MC, Hall S, et al. Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of GO-FORWARD trial. J Rheumatol. 2016;43(2):298–306. doi:10.3899/jrheum.150712.
5. Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012; 71(6):817–824. doi: 10.1136/ard.2011.200317.
6. Tanaka Y, Harigai M, Takeuchi T, et al. Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: pos hoc analysis of the GO-FORTH study. Mod Rheumatol. 2016;26(3):323–330. doi: 10.3109/14397595.2015.1086041.
7. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of Golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272–2283. doi: 10.1002/art.24638.
8. Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous Golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken). 2016;68(6):744–752. doi: 10.1002/acr.22759.
9. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicenter, randomised, doubleblind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–221. doi: 10.1016/S0140-6736(09)60506-7.
10. Smolen JS, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors; findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015;17:14. doi: 10.1186/s13075-015-0516-6.
11. Huffstutter JE, Kafka S, Brent LH, et al. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. Curr Med Res Opin. 2017;33(4):657–666. doi: 10.1080/03007995.2016.1277195.
12. Inman RD, Davis JC Jr, Heijde Dv, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–3412. doi: 10.1002/art.23969.
13. Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104- week results of the GO-RAISE study. Ann Rheum Dis. 2012;71(5): 661–667. doi: 10.1136/ard.2011.154799.
14. Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. Ann Rheum Dis. 2012;71(6):878–884. doi: 10.1136/annrheumdis-2011-200308.
15. Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis; results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014;73(6):1107–1113. doi: 10.1136/annrheumdis-2012-203075.
16. Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74(4): 757–761. doi: 10.1136/annrheumdis-2014-205862.
17. Sieper J, van der Hejide D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of sub cutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702–2712. doi: 10.1002/art.39257.
18. Bao C, Huang F, Khan MA, et al. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicenter, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford). 2014;53(9):1654–1663. doi: 10.1093/rheumatology/keu132.
19. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–986. doi: 10.1002/art.24403.
20. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689–1694. doi: 10.1136/annrheumdis-2013-204902.
21. Kruger K, Burmester GR, Wassenberg S, et al. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open. 2018;8(6):e021082. doi: 10.1136/bmjopen-2017-021082.
22.
Review
For citations:
Chichasova N.N. Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability. Current Pediatrics. 2018;17(6):449-457. (In Russ.) https://doi.org/10.15690/vsp.v17i6.1975
Views:
896
Email this article 
